Skip to Content

Teveten Side Effects

Generic Name: eprosartan

Note: This page contains side effects data for the generic drug eprosartan. It is possible that some of the dosage forms included below may not apply to the brand name Teveten.

It is possible that some side effects of Teveten may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

For the Consumer

Applies to eprosartan: oral tablet

As well as its needed effects, eprosartan (the active ingredient contained in Teveten) may cause unwanted side effects that require medical attention.

If any of the following side effects occur while taking eprosartan, check with your doctor immediately:

Less common
  • Burning or painful urination or changes in urinary frequency
  • cough
  • fever
  • sore throat
  • Dizziness, lightheadedness, or fainting
  • swollen face, lips, limbs, or tongue

Some eprosartan side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

Less common or rare
  • Abdominal or stomach pain
  • joint pain
  • unusual tiredness

For Healthcare Professionals

Applies to eprosartan: oral tablet


In general, eprosartan (the active ingredient contained in Teveten) has been well tolerated. Prior to FDA approval data have shown that the incidence of adverse drug events (ADEs) associated the use of eprosartan was similar to the incidence of ADEs associated with the use of placebo. The most frequently occurring ADEs that were considered to be associated with the use of eprosartan (but as prevalent among placebo patients) included headache, dizziness, myalgia, sinusitis, diarrhea, bronchitis, dyspepsia, edema, and chest pain. The majority of ADEs were mild to moderate in severity. In placebo-controlled trials, 4% of treated patients discontinued therapy due to an ADE, compared with 6.5% of patients given placebo.[Ref]

Nervous system

Nervous system side effects have included anxiety, ataxia, insomnia, migraine, neuritis, nervousness, paresthesia, somnolence, tremor, vertigo, and tinnitus in less than 1% of patients.[Ref]


Angiotensin II receptor blockade, unlike ACE inhibition, has no impact on the processing of peptides such as bradykinin and substance P, two peptides able to induce cough.

The incidence of cough was not significantly different and averaged 3.5% and 2.6%, respectively, in patients who were given eprosartan (the active ingredient contained in Teveten) and placebo. In comparative studies, the average incidence of cough among patients enalapril ranged from 6.1% to 12.8%, nearly two to three times the incidence of cough among patients given eprosartan (1.5% to 6.5%).[Ref]

Respiratory side effects have included upper respiratory tract infection (8%), rhinitis (4%), pharyngitis (4%), cough (4%), asthma (<1%), and epistaxis (<1%).[Ref]


Cardiovascular side effects of eprosartan (the active ingredient contained in Teveten) reported in less than 1% of patients have included angina pectoris, bradycardia, abnormal ECG, extrasystoles, atrial fibrillation, hypotension (including orthostatic hypotension), tachycardia, palpitations, and peripheral ischemia.[Ref]


Metabolic side effects have included hypertriglyceridemia (1%); and increased creatine phosphokinase, diabetes mellitus, glycosuria, gout, hypercholesterolemia, hyperglycemia, hyperkalemia, hypokalemia, and hyponatremia in less than 1% of patients.[Ref]


Dermatologic side effects reported in less than 1% of patients have included eczema, furunculosis, pruritus, rash, and maculopapular rash.[Ref]


Gastrointestinal side effects have included abdominal pain (2%). Anorexia, constipation, dry mouth, esophagitis, flatulence, gastritis, gastroenteritis, gingivitis, nausea, periodontitis, toothache, and vomiting have been reported in less than 1% of patients. A case of dysgeusia and burning mouth syndrome has been reported.[Ref]


Musculoskeletal side effects have included arthralgia (2%), arthritis, arthrosis, skeletal pain, tendonitis, leg cramps, and back pain in less than 1% of patients. In addition, rare reports of rhabdomyolysis have been reported during postmarketing experience in patients receiving angiotensin II receptor blockers.[Ref]


Hematologic side effects have included anemia and purpura in less than 1% of patients, decrease in hemoglobin of more than 20% (0.1%), leukopenia (0.3%), neutropenia (1.3%), and thrombocytopenia (0.3%).[Ref]


Hepatic side effects have included minor increases in AST (SGOT), ALT (SGPT), and alkaline phosphatase in less than 1% of patients. One case of elevated ALT >3.5 times ULN has been reported.[Ref]


Renal side effects have included minor increases in creatinine (0.6%) and BUN (1.3%). The use of angiotensin II receptor antagonists in patients whose renal function depends on the renin-angiotensin-aldosterone system (i.e., congestive heart failure) has been associated with oliguria and/or progressive azotemia and rarely acute renal failure and/or death. Increases in serum creatinine and BUN have been reported with other angiotensin II receptor antagonists in patients with unilateral or bilateral renal artery stenosis.[Ref]


Endocrine side effects have included increased sweating in less than 1% of patients.[Ref]


Ocular side effects have included conjunctivitis, abnormal vision, and xerophthalmia in less than 1% of patients.[Ref]


Psychiatric side effects have included depression (1%).[Ref]


Genitourinary side effects have included urinary tract infection (1%). Albuminuria, cystitis, hematuria, micturition frequency, polyuria, renal calculus, and urinary incontinence have been reported in less than 1% of patients.[Ref]


Side effects affecting the body as a whole have included viral infection (2%), injury (2%), and fatigue (2%). Alcohol intolerance, asthenia, substernal chest pain, peripheral edema, fever, hot flushes, influenza-like symptoms, malaise, rigors, pain, herpes simplex, otitis externa, and otitis media have been reported in less than 1% of patients.[Ref]


1. Gavras I, Gavras H "Safety and tolerability of eprosartan." Pharmacotherapy 19 (1999): s102-7

2. Oparil S "Eprosartan versus enalapril in hypertensive patients with angiotensin-converting enzyme inhibitor-induced cough." Curr Ther Res Clin Exp 60 (1999): 1-14

3. "Product Information. Teveten (eprosartan)." SmithKline Beecham, Philadelphia, PA.

4. Waeber B, Burnier M, Nussberger J, Brunner HR "Experience with angiotensin II antagonists in hypertensive patients." Clin Exp Pharmacol Physiol 23 ( Suppl (1996): s142-6

5. Ilson BE, Martin DE, Boike SC, Jorkasky DK "The effects of eprosartan, an angiotensin II AT(1) receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension." J Clin Pharmacol 38 (1998): 437-41

6. Castells X, Rodoreda I, Pedros C, Cereza G, Laporte JR "Drug points: Dysgeusia and burning mouth syndrome by eprosartan." BMJ 325 (2002): 1277

7. Burnier M, Roch-Ramel F, Brunner HR "Renal effects of angiotensin II receptor blockade in normotensive subjects." Kidney Int 49 (1996): 1787-90

8. Ziai F, Ots M, Provoost AP, Troy JL, Rennke HG, Brenner BM, Mackenzie HS "The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure." Kidney Int Suppl 57 (1996): s132-6

9. Burnier M, Hagman M, Nussberger J, Biollaz J, Armagnac C, Brouard R, Weber B, Brunner HR "Short-term and sustained renal effects of angiotensin II receptor blockade in healthy subjects." Hypertension 25 (1995): 602-9

10. van den Meiracker AH, Admiraal PJ, Janssen JA, Kroodsma JM, de Ronde WA, Boomsma F, Sissmann J, Blankestijn PJ, Mulder PG, Man In 't Veld AJ "Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension." Hypertension 25 (1995): 22-9

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.